Bial and Eisai have announced data which confirm the effectiveness and tolerability of Zebinix® (eslicarbazepine acetate) in routine clinical practice.
The Euro-Esli study is an exploratory pooled analysis of data from 14 European clinical practice studies, analysing data of 2058 patients aged between 14-88 years old with partial-onset seizures (POS), with or without secondary generalisation. Full results were presented at the IEC in Barcelona, Spain.
The Euro-Esli study, which included over 2000 patients with epilepsy, showed that at three, six and 12 months, seizure freedom rates in patients aged 14-88 years treated with eslicarbazepine acetate were 30.6%, 38.3% and 41.3% respectively.
Retention rates were 95.4%, 86.6% and 73.4% and responder rates were 60.9%, 70.5% and 75.6%, respectively.
There were significant reductions from baseline to final visit in monthly frequencies of total (mean reduction 44.1%), simple partial (78.8%), complex partial (53.1%) and secondarily generalised (80.0%) seizures.
Dr Vicente Villanueva, Neurologist and Epileptologist, Hospital Universitario y Politécnico La Fe, Valencia, Spain, said: “It is most reassuring to see similar efficacy results with eslicarbazepine acetate in a routine clinical setting compared to that of clinical trials; we can be confident that this treatment is effective amongst the diversity of our ‘real’ epilepsy patients.”
Eslicarbazepine acetate is indicated as monotherapy in the treatment of POS, with or without secondary generalisation, in adults with newly diagnosed epilepsy; and as adjunctive therapy in adults, adolescents, and children aged above six years, with POS with or without secondary generalisation.
Epilepsy affects approximately six million people in Europe. It has many possible causes but often the cause is unknown.